Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.61 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | P4HB | P07237 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8307140 | 0.85 | GRM5 (0.69) | GRM5ASIC3KDM4EKMT2AMEN1 | |
| SCHEMBL13689760 | 0.78 | KMT2A (0.66) | KDM4EKMT2AMEN1KDRRAB9A | |
| SCHEMBL16264676 | 0.77 | GRM5 (0.58) | GRM5ASIC3KDM4EKMT2AMEN1 | |
| SCHEMBL5582792 | 0.76 | GRM5 (1.00) | GRM5ASIC3 | |
| SCHEMBL16245591 | 0.74 | ULK1 (0.49) | GRM5ASIC3KDM4ERAB9AGAA | |
| SCHEMBL16245883 | 0.74 | GRM5 (0.49) | GRM5ASIC3KDR | |
| SCHEMBL1702467 | 0.74 | GRM5 (0.62) | GRM5ASIC3KDM4EKDRPDE10A | |
| SCHEMBL27311239 | 0.73 | SLC2A1 (0.50) | KDM4EKMT2AMEN1KDRPDE10A | |
| SCHEMBL19681546 | 0.72 | GRM5 (0.50) | GRM5ASIC3KMT2AMEN1KDR | |
| SCHEMBL11970994 | 0.72 | KDR (0.57) | GRM5ASIC3KMT2AMEN1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870624-B2 | Histone deacetylase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2020-12-22 | — | — | US | disclosed |
| US-10870624-B2 | Histone deacetylase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2020-12-22 | — | — | US | disclosed |
| US-20200316062-A1 | COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2020-10-08 | — | — | US | disclosed |
| US-20200316062-A1 | COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2020-10-08 | — | — | US | disclosed |
| EP-3456355-A1 | COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR | Karus Therapeutics Ltd (GB) | 2019-03-20 | — | — | EP | disclosed |
| EP-3456355-A1 | COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR | Karus Therapeutics Ltd (GB) | 2019-03-20 | — | — | EP | disclosed |
| US-20180243317-A1 | COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR | KARUS THERAPEUTICS LTD (GB) | 2018-08-30 | — | — | US | disclosed |
| EP-3337484-A1 | COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR | Karus Therapeutics Ltd (GB) | 2018-06-27 | — | — | EP | disclosed |
| US-20180170876-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| US-20180170876-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| US-20180170876-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| US-9862685-B2 | Histone deacetylase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2018-01-09 | — | — | US | disclosed |
| US-9862685-B2 | Histone deacetylase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2018-01-09 | — | — | US | disclosed |
| WO-2017208032-A1 | COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LTD (GB) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017029514-A1 | COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR | KARUS THERAPEUTICS LTD (GB) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017029514-A1 | COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR | KARUS THERAPEUTICS LTD (GB) | 2017-02-23 | — | — | WO | disclosed |
| US-20160096804-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2016-04-07 | — | — | US | disclosed |
| US-20160096804-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2016-04-07 | — | — | US | disclosed |
| US-20160096804-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2016-04-07 | — | — | US | disclosed |
| WO-2014181137-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LTD (GB) | 2014-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096804-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC5, HDAC11 | GRM5 2758/4885ASIC3 1433/4885KDM4E 146/4885 |
| US-20180243317-A1 | COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR | HDAC1, HDAC9, HDAC5 | GRM5 2196/4885ASIC3 1066/4885KDM4E 348/4885 |
| US-20180170876-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC5, HDAC11 | GRM5 2758/4885ASIC3 1433/4885KDM4E 146/4885 |
| US-10870624-B2 | Histone deacetylase inhibitors | HDAC1, HDAC5, HDAC2 | GRM5 2397/4885ASIC3 1402/4885KDM4E 133/4885 |
| US-20200316062-A1 | COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS | MCL1, HDAC1, MYC | GRM5 4310/4885ASIC3 4645/4885KDM4E 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.